To find a reference on this page either scroll or hold down the "Ctrl" key and press "f".
|
abacavir
|
| HIV - Ziagen (New drug) 22(5) 125-7 |
| lamivudine - zidovudine combination - Trizvir (New combination) 24(6) 155-8 |
|
abatacept
|
| rheumatoid arthritis - Orencia (New drug) 30(6) 163-7 |
|
abciximab
|
| in antiplatelet therapy 19(4) 98-101 |
| coronary angioplasty - ReoPro (New drug) 19(3) 81-3 |
|
Abilify
|
| see aripiprazole 26(5) 118-9 |
|
abnormal laboratory results - see also diagnostic tests
|
| abnormal haematology results in children 27(3) 64-6 |
| 'Abnormal laboratory results' - book review 25(2) 28 |
| abnormalities in pregnancy 29(2) 48-52 |
| letter 29(4) 91-3 |
| adrenocortical function in adults 30(6) 147-9 |
| allergy testing 25(4) 91-3 |
| antibodies to cyclic citrullinated peptides in rheumatoid arthritis 29(6) 162-4 |
| biochemical tests in pregnancy 28(4) 98-101 |
| letters 29(1) 3-5; 28(6) 136-9 |
| cardiac markers 26(4) 88-90 |
| cell markers 30(5) 128-9 |
| congestive heart failure and B-type natriuretic peptide 26(3) 64-5 |
| C-reactive protein 30(3) 74-6 |
| creatinine clearance and renal function 24(1) 15-7 |
| drug screens 24(4) 90-1 |
| fertility testing 25(2) 38-40 |
| haemostasis disorders 18(2) 38-41 |
| dental implications 18(2) 48 |
| HDL cholesterol 17(4) 99-102 |
| Sheffield tables 21(4) 98-9 |
| Helicobacter pylori 20(4) 96-8 |
| letter 21(2) 31-4 |
| hepatitis B 21(3) 72-5 |
| dental implications 21(3) 79 |
| hepatitis C 22(4) 91-4 |
| iron deficiency 20(3) 74-6 |
| magnesium 30(4) 102-5 |
| letter 30(6) 140-41 |
| paediatric biochemical tests 28(5) 126-9 |
| prostate specific antigen - costs of tests (letter) 17(1) 4-5 |
| sensitivity and specificity 26(5) 111-13; 25(5) 107 |
| letter 25(6) 131-2 |
| sexually transmitted infections 30(1) 8-13 |
| thalassaemia screening 24(5) 120-3 |
| letter 25(2) 27-8 |
| thrombophilia 22(3) 63-6 |
|
abnormalities, congenital - see birth defects
|
|
Aboriginal children
|
| medication compliance (letter) 26(2) 27-9 |
|
Aboriginal people
|
| Aboriginal primary health care (book review) 27(1) 9 |
| CARPA Standard Treatment Manual (book review) 27(1) 8 |
| drug therapy 26(5) 106-9 |
| letter 27(3) 55-7 |
| medication management 28(5) 123-5 |
| letters 29(6) 149-50; 29(3) 59-62 |
|
acamprosate
|
| alcohol dependence 25(3) 70-3 |
| Campral (New drug) 22(6) 147-51 |
|
acarbose
|
| antidiabetic - Glucobay (New drug) 21(2) 49-55 |
| drug interactions 24(4) 83-5 |
|
Accolate
|
| see zafirlukast 22(3) 50-1; 22(2) 43-7 |
|
Accuretic
|
| see quinapril 25(5) 120-3 |
|
ACE inhibitors
|
| cilazapril - Inhibace (New drug) 20(2) 45-51 |
| distribution in human milk 20(2) 35-40 |
| in early management of myocardial infarction 19(2) 52-4 |
| effects on kidney 23(1) 17-9 |
| letter 22(3) 53-4 |
| in heart failure 23(6) 118-20 |
| clinical pharmacology (editorial) 19(1) 2-3 |
| in hypertension in diabetes 25(1) 8-10 |
| letter 25(3) 51-3 |
| in post-myocardial infarct patients 19(1) 8-10 |
| and renal failure (letter) 18(2) 27-9 |
| trandolapril - Odrik (New drug) 17(4) 87-90 |
| in type 2 diabetic hypertension 20(3) 65-7 |
| vs angiotensin receptor antagonists in hypertension 21(4) 95-7 |
| vs diuretics in hypertension 27(4) 98-101 |
|
acetazolamide
|
| in glaucoma 25(6) 142-6 |
|
acetylcholinesterase inhibitors
|
| donepezil - Alzheimer's disease - Aricept (New drug) 22(1) 20-3 |
| donepezil in Alzheimer's disease (editorial) 28(6) 134-5 |
| letter 29(3) 59-62 |
| galantamine - Alzheimer's disease - Reminyl (New drug) 24(4) 100-2 |
| rivastigmine - Alzheimer's disease - Exelon (New drug) 23(5) 110-1 |
| tacrine - Alzheimer's disease - Cognex (New formulation) 18(2) 35-8 |
| tacrine in Alzheimer's disease 19(1) 14-7 |
|
aciclovir
|
| Aciclovir Intravenous Infusion (New brand) 22(5) 125-7 |
| Zyclir (New brand) 25(4) 94-9 |
|
Acimax
|
| see omeprazole 23(1) 21-3 |
|
acitretin
|
| psoriasis and keratinisation disorders - Neotigason (New drug) 18(4) 86-7 |
|
Aclor
|
| see cefaclor 27(1) 21-3 |
|
acne
|
| adapalene - Differin (New drug) 20(2) 45-51 |
| azelaic acid - Skinoren (New drug) 17(1) 6-8 |
| isotretinoin in cystic acne 28(3) 59-61 |
| polycystic ovary syndrome 27(5) 129-31 |
| tazarotene - Zorac (New drug) 29(3) 84-7 |
|
acromegaly
|
| lanreotide - Somatuline LA (New drug) 25(2) 44-7 |
|
ACTH
|
| see adrenocorticotrophic hormone 30(6) 147-9 |
|
activated charcoal
|
| in doctor's bag supplies (PBAC question) 20(4) 86-7 |
| in poisoning 20(1) 14-6 |
|
Actonel
|
| see risedronate 24(1) 20-3 |
|
Actos
|
| see pioglitazone 25(1) 20-3 |
|
acute care, domiciliary
|
| hospital in the home 20(4) 88-9 |
|
acute-phase reaction
|
| C-reactive protein 30(3) 74-6 |
|
acyclovir
|
| genital herpes (letter) 17(2) 28-9 |
| new brand - Zyclir 18(1) 7-9 |
| new formulation - Zovirax 20(1) 22-3 |
| valaciclovir - acyclovir ester - herpes zoster - Valtrex (New drug) 19(4) 108-11 |
|
Adalat
|
| see nifedipine 17(4) 87-90 |
|
adalimumab
|
| Humira - rheumatoid arthritis (New drug) 27(4) 101-5 |
| rheumatoid arthritis 27(2) 43-6 |
| tumour necrosis factor blockers in rheumatology 29(3) 67-70 |
|
adapalene
|
| acne - Differin (New drug) 20(2) 45-51 |
|
Addison's disease
|
| abnormal laboratory results 30(6) 147-9 |
|
adefovir dipivoxil
|
| Hepsera - hepatitis B (New drug) 27(6) 159-65 |
|
Adenocor
|
| see adenosine 18(2) 35-8 |
|
adenosine
|
| in doctor's bag supplies (PBAC question) 20(4) 86-7 |
| supraventricular tachycardia - Adenocor (New drug) 18(2) 35-8 |
|
adrenal cortex hormones
|
| pharmacology 19(2) 41-4 |
|
adrenal gland cancer
|
| iobenguane - MIBGen - tumour localisation (New drug) 27(5) 131-3 |
|
adrenaline
|
| dilution strength in anaphylaxis (PBAC question) 18(3) 59 |
| in heart failure 23(6) 118-20 |
| management of anaphylaxis - wallchart 30(5) 115; 24(5) 112 |
| management of cardiac arrest 20(2) 41-5 |
| repeat prescriptions of EpiPen auto-injectors (PBAC question) 28(4) 90 |
| shelf-life of EpiPen (PBAC question) 29(2) 52-3 |
|
adrenocorticotrophic hormone
|
| abnormal laboratory results 30(6) 147-9 |
|
adverse effects - see also birth defects; drug interactions
|
| ACE inhibitors and renal failure (letter) 18(2) 27-9 |
| Adverse Drug Reactions Advisory Committee 28(6) 140-2 |
| Adverse Medicine Events Line 28(4) 102; 27(2) 38 |
| adverse reaction reporting 28(6) 140-2 |
| dental notes 28(6) 142 |
| alcohol and paracetamol hepatotoxicity 27(1) 14-5 |
| alendronate and oesophagitis in older patients (letter) 21(1) 5-8 |
| amiodarone in arrhythmia 28(6) 150-4 |
| amoxycillin clavulanic acid combination (letter) 17(3) 55-6 |
| angiotensin receptor antagonists (letter) 22(3) 53-4 |
| anticonvulsants for neuropathic pain 22(6) 140-1 |
| letter 23(4) 72 |
| antidepressants and serotonin syndrome 21(3) 63 |
| letters 22(3) 53-4; 21(1) 5-8 |
| antidepressants and sleep disorders in the elderly 18(1) 21-2 |
| antidepressants in pregnancy and breastfeeding 30(5) 125-7 |
| antiepileptics - teratology and dental implications 17(1) 12 |
| antifungal agents and latex in condoms 23(6) 129 |
| antineoplastics 18(4) 105-7; 18(3) 65-7 |
| in the aged 23(4) 80-2 |
| dental implications 23(4) 83 |
| personal experience 23(4) 82-3 |
| cancer treatment in the 21st century (editorial) 23(1) 5 |
| letter 23(3) 55-6 |
| letter - doxorubicin and radiotherapy 19(2) 36-8 |
| letter - Oralmat Drops for oral pain relief 19(2) 36-8 |
| antipsychotic drugs |
| atypical vs typical 27(6) 146-9; 27(6) 149-51 |
| in pregnancy and breastfeeding 30(6) 162-3 |
| and risk of diabetes 27(5) 118-9 |
| aspirin and NSAID interactions 20(4) 90 |
| aspirin, alcohol and gastric bleeding 28(1) 18-9 |
| letter 28(4) 84-7 |
| asthma with ibuprofen 27(4) 87 |
| benefit vs harm evaluation in drug therapy 24(1) 18 |
| benzodiazepine interactions with neuroleptics and hypnotics 20(1) 5-8 |
| benzodiazepines (letter) 18(3) 56-7 |
| bisphosphonates and avascular necrosis of the jaw (letter) 27(2) 28-33 |
| bisphosphonates and osteonecrosis of the jaws 30(4) 96-7 |
| bowel cleaning preparations 28(1) 16-7 |
| bruising with miconazole oral gel 26(2) 35 |
| cabergoline-induced valvulopathy 31(1) 21 |
| calcium channel antagonists 20(1) 5-8 |
| and risk of myocardial infarction (editorials) 22(1) 2-3; 19(2) 35 |
| carbamazepine and cytopenia 25(3) 73-4 |
| letter 25(5) 104-7 |
| cefaclor and serum sickness (letter) 22(2) 28-31 |
| celecoxib prescriptions and adverse effects (PBAC question) 24(1) 7-8 |
| correction 24(3) 64 |
| cephalosporins and penicillin allergy 30(1) 25-6 |
| cerivastatin, gemfibrozil and rhabdomyolysis 24(5) 109 |
| Chinese medicines 26(6) 128-30 |
| letter 27(2) 28-33 |
| chiral drugs - pharmacology and efficacy 27(2) 47-9 |
| letter 27(5) 109-13 |
| chloramphenicol and aplastic anaemia (letters) 20(1) 3-4; 19(3) 59-62; 19(1) 3-6 |
| ciprofloxacin and fever (letter) 28(6) 136-9 |
| cisapride 23(3) 59 |
| and arrhythmias 25(6) 135 |
| letter 23(5) 93-6 |
| complementary medicines |
| editorial 25(3) 50-1 |
| letter 26(2) 27-9 |
| regulation 21(4) 107-8 |
| consumer perceptions of risk 26(2) 44-5; 26(1) 20-1 |
| corticosteroids |
| in autoimmune diseases 22(1) 9-11 |
| in dermatology 21(1) 9-11 |
| in rheumatology 21(1) 11-4 |
| cross-reactivity of penicillins and cephalosporins 30(1) 25-6 |
| cyclo-oxygenase inhibitors 23(2) 30-2 |
| cytochrome P450 system and drug interactions 24(1) 10-2 |
| letters 24(4) 80-2 |
| cytotoxic therapy 18(4) 105-7; 18(3) 65-7 |
| letter - doxorubicin and radiotherapy 19(2) 36-8 |
| letter - Oralmat Drops for oral pain relief 19(2) 36-8 |
| digoxin - brands and dosages 29(6) 153 |
| letter 30(2) 32-4 |
| digoxin in congestive heart failure 22(6) 136-7 |
| letter 23(3) 55-6 |
| dihydropyridines and nocturia 20(1) 3-4 |
| disodium pamidronate and breast disease (letter) 22(2) 28-31 |
| drug allergy testing 17(3) 62-5 |
| letter - vaccines and egg protein allergy 18(2) 27-9 |
| drugs in human milk 20(2) 35-40 |
| dental implications 20(2) 51 |
| letters 21(4) 87-91; 21(2) 31-4; 21(1) 5-8; 20(4) 83-6 |
| drugs which lower seizure threshold 24(1) 8-9 |
| letters 24(5) 107-9; 24(3) 51-5 |
| drugs which prolong the QTC interval 25(3) 63-5 |
| dystonic reactions to drugs 24(1) 19-20 |
| fenofibrate-warfarin interactions 29(6) 166 |
| letter 30(2) 32-4 |
| flucloxacillin and cholestatic hepatitis (editorial) 18(3) 54-6 |
| letter 19(1) 3-6 |
| generic prescribing and prescription errors (letter) 17(4) 79-81 |
| gingival bleeding 29(6) 154-5 |
| gingival enlargement 26(1) 11-3 |
| guarana preparations and caffeine (letter) 21(1) 5-8 |
| headache and analgesic overuse 28(6) 143-5 |
| letter 29(3) 59-62 |
| hepatotoxicity of ranitidine, diclofenac and phenytoin (letter) 19(4) 92-3 |
| histamine H2 receptor antagonists - allergy 23(6) 123 |
| hormone replacement in menopause - carcinogenic risks (letter) 17(1) 4-5 |
| hyponatraemia 26(5) 114-7 |
| letters 27(3) 55-7; 27(2) 28-33 |
| with omeprazole 28(2) 48-9 |
| ibuprofen and asthma 27(4) 87 |
| interstitial nephritis with omeprazole 30(3) 67 |
| intravenous potassium chloride 28(1) 14-6 |
| letters 28(4) 84-7 |
| isotretinoin in acne 28(3) 59-61 |
| kidney impairment and everyday drugs 23(1) 17-9 |
| legal issues 25(5) 114-5 |
| lindane toxicity and treatment of ectoparasites (letters) 21(1) 3-4; 20(2) 31-2 |
| low molecular weight heparins 19(4) 104-8 |
| correction 20(1) 20-1 |
| MedicAlert (letter) 18(4) 84-6 |
| MedSafety online learning system for medication error prevention (letter) 27(5) 109-13 |
| metformin in pregnancy and lactation 30(3) 68-9 |
| methotrexate 23(2) 44-5 |
| letter 23(5) 93-6 |
| metronidazole and breastfeeding (letter) 28(2) 29-33 |
| muscle symptoms with simvastatin 28(4) 102 |
| neurocognitive effects of chemotherapy 31(1) 22-4 |
| neuropathy (letter) 23(4) 72 |
| neutropenia with quetiapine 31(1) 10-11 |
| nifedipine and gingival hyperplasia (letter) 17(1) 6-8 |
| nitrofurantoin risks and benefits (letter) 27(4) 82-3 |
| NSAIDS and cardiovascular disease in rheumatology (editorial) 29(4) 90-1 |
| oestrogens - menopause 26(1) 8-10; 23(5) 90-2 |
| and older persons (editorial) 22(6) 130-1 |
| omeprazole and hyponatraemia 28(2) 48-9 |
| omeprazole and interstitial nephritis 30(3) 67 |
| online reporting 28(6) 140-2; 26(1) 5-7 |
| by consumers 27(2) 38 |
| osteonecrosis of the jaws with bisphosphonates 30(4) 96-7 |
| overdoses of over-the-counter Donnalix Infant Drops 29(3) 83 |
| paracetamol and NSAIDs interactions 20(3) 74 |
| paracetamol, gastrointestinal bleeding and hypertension (letter) 30(3) 59-63 |
| pertussis vaccination (letter) 18(3) 56-7 |
| pethidine |
| in chronic pain 25(1) 12-3 |
| letter 25(4) 79-80 |
| in migraine 20(3) 71 |
| letter 21(2) 31-4 |
| pitfalls of prescribing generic drugs (letter) 28(4) 84-7 |
| polypharmacy (editorial) 31(1) 2-3 |
| prazosin and postural hypotension 18(1) 21-2 |
| progestogen-only contraceptives 22(1) 6-8 |
| salmeterol (editorial) 29(5) 118-9 |
| serotonin syndrome 26(3) 62-3; 25(1) 19 |
| letter 26(5) 99-102 |
| over-the-counter dextromethorphan 29(3) 71 |
| letter 29(6) 149-50 |
| simvastatin and muscle symptoms 28(4) 102 |
| letter 28(6) 136-9 |
| splitting tablets 25(6) 133-5 |
| letters 26(2) 27-9 |
| starter packs and drug samples 30(1) 14-16 |
| statins and muscle damage (editorial) 26(4) 74-5 |
| sulfonamide allergy and cross-reactivity 31(1) 8-10 |
| temazepam capsules and injecting drug users 27(3) 58-9 |
| letter 27(5) 109-13 |
| thiazide diuretics |
| in hypertension (editorial) 22(5) 102-3 |
| and osteoporosis 24(3) 65-7 |
| thiazolidinediones 27(3) 67-70; 27(3) 70-4 |
| letter 27(6) 138-41 |
| thyroid dysfunction and amiodarone, phenytoin and lithium 17(3) 70-2 |
| thyroxine in subclinical hypothyroidism 22(6) 132-4 |
| toothpaste 17(2) 49-51 |
| letter 18(1) 4-7 |
| toxicity with Donnalix Infant Drops 29(3) 83 |
| tramadol |
| editorial 27(2) 26-7 |
| and hyponatraemia 27(4) 97 |
| letter 28(2) 29-33 |
| and serotonin syndrome 25(1) 19 |
| vascular effects of COX-2 selective inhibitors 27(6) 142-5 |
| letters 28(2) 29-33 |
| warfarin |
| bioequivalence and haemorrhage risk (letters) 26(2) 27-9; 22(5) 103-5 |
| interactions with miconazole 26(2) 33-5 |
| and occult bleeding 24(4) 89 |
| risks and benefits 27(4) 88-92 |
| cataract surgery (letter) 27(6) 138-41 |
| xerostomia, drugs and radiotherapy 29(4) 97-8 |
| dental notes 29(4) 108 |
| letters 30(1) 3-4 |
|
Adverse Medicine Events Line
|
| Adverse Medicine Events Line 27(2) 38 |
| consumer reporting of adverse drug reactions 28(4) 102 |
| starter packs and adverse effects 30(1) 14-16 |
|
advertising
|
| AdWatch website review 27(3) 63 |
| complementary medicines (letter) 30(6) 140-41 |
| direct-to-consumer advertising 27(1) 4-6 |
| in New Zealand 29(2) 30-2 |
| drug advertising and clinical software 23(3) 52-3 |
| drug advertising and consumers |
| editorial 22(4) 74-5 |
| internet 23(4) 73-4; 23(4) 75 |
| letter 24(4) 80-2 |
| drug advertising and the media (editorial) 23(4) 70-1 |
| letter 23(6) 115-7 |
| drug industry code of conduct 25(2) 41; 24(2) 42-3; 23(5) 97-9; 22(4) 78-80 |
| letter 25(4) 79-80 |
| pharmaceutical representatives 23(5) 97-9 |
| effectiveness of new drugs (editorial) 27(1) 2-3 |
| efficacy of Ginkgo biloba in tinnitus (letter) 30(2) 32-4 |
| electronic prescribing 23(3) 52-3 |
| gabapentin promotion and off-label prescribing 26(1) 18-9 |
| editorial comment 26(1) 18-9 |
| letters 27(4) 82-3; 26(3) 51-2; 26(2) 27-9 |
| independent drug bulletins (editorial) 25(1) 3-4 |
| letter 25(3) 51-3 |
| marketing strategies of drug industry 19(4) 103 |
| medical journals (letter) 17(1) 4-5 |
| Medicines Australia - code of conduct breaches 30(6) 153-5; 29(6) 164-5; 29(1) 16-7; 27(6) 141; 27(5) 124-7; 27(3) 60; 27(1) 6-7; 26(3) 66; 26(3) 67 |
| vardenafil 30(6) 154 |
| regulatory framework in Australia 27(5) 124-7 |
| retail pharmacy promotions (letter) 27(2) 28-33; 26(5) 99-102 |
|
advertising standards
|
| drug industry and product information 18(1) 19-21 |
| specific drugs - amoxycillin clavulanic acid combination - Augmentin - (letter) 17(3) 55-6 |
|
AdWatch
|
| website review 27(3) 63 |
|
Aerodiol
|
| see oestradiol 26(5) 118-9 |
|
Aethoxysklerol
|
| see laureth-9 25(1) 20-3 |
|
agalsidase alfa
|
| Replagal - Fabry's disease (New drug) 27(5) 131-3 |
|
agalsidase beta
|
| Fabrazyme - Fabry's disease (New drug) 27(5) 131-3 |
|
aged
|
| alendronate and oesophagitis (letter) 21(1) 5-8 |
| anaesthesia and perioperative care 25(2) 42-4 |
| antineoplastics - adverse effects 23(4) 80-2 |
| dental implications 23(4) 83 |
| personal experience 23(4) 82-3 |
| Australian Medicines Handbook 'Aged Care Companion' (book review) 26(6) 143 |
| beta blockers in hypertension 30(1) 5-7 |
| geriatrics in the 21st century (editorial) 23(1) 3 |
| influenza immunisation 25(1) 5-7 |
| laxatives (PBAC question) 26(2) 30-2 |
| management of depression 24(3) 65-7 |
| management of undernutrition 24(5) 113-5 |
| Pharmaceutical Benefits Scheme restrictions on analgesics (PBAC question) 27(6) 155 |
| update 28(1) 13 |
| polypharmacy (editorial) 31(1) 2-3 |
| prescribing and older persons (editorial) 22(6) 130-1 |
|
ageing
|
| antioxidants and nutrition 22(6) 142-4 |
| melatonin 20(4) 98 |
|
Agenerase
|
| see amprenavir 25(2) 44-7 |
|
Aggrastat
|
| see tirofiban 22(4) 95-8 |
|
agnus castus
|
| agoraphobia 23(6) 124-6 |
| and premenstrual syndrome 24(5) 123 |
|
agoraphobia
|
| agoraphobia 23(6) 124-6 |
|
Agrylin
|
| see anagrelide 23(2) 45-6 |
|
AIDS - see HIV/AIDS
|
|
Airomir
|
| see salbutamol 22(1) 20-3 |
|
Alatrofloxacin
|
| see trovafloxacin 22(2) 43-7 |
|
Albumex 4
|
| see albumin, human 20(3) 77-9 |
|
albumin, human serum solution
|
| new formulation - Albumex 4 20(3) 77-9 |
|
alcohol
|
| aspirin and gastric bleeding 28(1) 18-9 |
| letter 28(4) 84-7 |
| distribution in human milk 20(2) 35-40 |
|
alcohol dependence
|
| acamprosate - Campral (New drug) 22(6) 147-51 |
| management in general practice 25(3) 70-3 |
| thiamine deficiency (letter) 25(5) 104-7 |
| naltrexone - opioid antagonist - ReVia (New drug) 22(2) 43-7 |
| letter 22(5) 103-5 |
| paracetamol hepatotoxicity 27(1) 14-5 |
|
Aldara
|
| see imiquimod 22(1) 20-3 |
|
aldesleukin
|
| renal cell carcinoma - Proleukin (New drug) 23(4) 84-7 |
|
aldosterone
|
| abnormal laboratory results 30(6) 147-9 |
| pharmacology 19(2) 41-4 |
|
Aldurazyme
|
| see laronidase 30(3) 79-82 |
|
alefacept
|
| amevive - chronic plaque psoriasis (New drug) 27(4) 101-5 |
|
alemtuzumab
|
| MabCampath - chronic lymphocytic leukaemia (New drug) 29(6) 167-71 |
|
alendronate
|
| bisphosphonates and osteoporosis (PBAC question) 24(2) 41 |
| bone resorption inhibitor - Fosamax (New drug) 19(4) 108-11 |
| Fosamax (New strength) 24(4) 100-2; 23(4) 84-7 |
| oesophagitis in older patients (letter) 21(1) 5-8 |
| osteoporosis 23(6) 133-6 |
|
alfentanil
|
| opioid analgesic - Rapifen (New drug) 20(2) 45-51 |
|
alginates
|
| as wound dressings 19(1) 11-3 |
|
alglucerase
|
| enzyme replacement - Gaucher's disease - Ceredase (New drug) 18(1) 7-9 |
| vs imiglucerase in Gaucher's disease 22(4) 95-8 |
|
Alimta
|
| see pemetrexed disodium 28(1) 19-23 |
|
allergy
|
| immunotherapy 26(4) 91-3 |
| monoclonal antibodies 29(5) 130-3 |
| penicillins and cephalosporins (medicinal mishap) 30(1) 25-6 |
| sulfonamide allergy and cross-reactivity 31(1) 8-10 |
| testing - abnormal laboratory results 25(4) 91-3 |
| testing for drug allergy 17(3) 62-5 |
| latex (letter) 18(1) 4-7 |
| vaccines and egg protein allergy (letter) 18(2) 27-9 |
|
Allermax
|
| see mometasone 24(2) 43-7 |
|
allopurinol
|
| azathioprine interactions 22(1) 19 |
| new brand - Allorin 18(1) 7-9 |
| in renal calculi 19(4) 94-7 |
|
Allorin
|
| see allopurinol 18(1) 7-9 |
|
alpha agonists
|
| brimonidine - glaucoma - Alphagan (New drug) 22(2) 43-7 |
|
alpha blockers
|
| doxazosin (letter) 23(6) 115-7 |
| postural hypotension 18(1) 21-2 |
| prostatic hypertrophy 18(2) 30-2 |
| tamsulosin hydrochloride - Flomax (New drug) 23(3) 64-7 |
|
alpha fetoprotein
|
| biochemical tests for abnormalities in pregnancy 29(2) 48-52 |
|
alpha reductase inhibitors
|
| in prostatic hypertrophy 18(2) 30-2 |
|
alpha-1-antitrypsin deficiency
|
| chronic obstructive pulmonary disease (letter) 30(6) 140-41 |
|
Alphagan
|
| see brimonidine 22(2) 43-7 |
|
Alphapril
|
| see enalapril maleate 24(2) 43-7 |
|
Alprax
|
| see alprazolam 25(6) 147-51 |
|
alprazolam
|
| Alprax (New brand) 25(6) 147-51 |
| new strength Xanax 20(1) 22-3 |
|
alprostadil
|
| erectile dysfunction - Caverject (New drug) 18(3) 58-9 |
| erectile dysfunction - Caverject (New strength) 22(2) 43-7; 18(3) 58-9 |
| erectile dysfunction - MUSE (New formulation) 22(2) 43-7 |
|
alternative medicines - see complementary medicines
|
|
Alvesco
|
| see ciclesonide 28(4) 104-6 |
|
Alzheimer's disease
|
| donepezil (editorial) 28(6) 134-5 |
| letter 29(3) 59-62 |
| donepezil - Aricept (New drug) 22(1) 20-3 |
| galantamine - Reminyl (New drug) 24(4) 100-2 |
| hormone replacement therapy 23(5) 90-2 |
| management of behavioural problems 28(3) 67-70 |
| memantine - Ebixa - (New drug) 26(5) 118-9 |
| mental status testing 28(1) 11-3 |
| patient support organisations 28(3) 72; 19(1) 17 |
| positron emission tomography 18(1) 15-8 |
| risks and hormone replacement therapy 23(5) 90-2 |
| risperidone for behavioural disturbances (RADAR comment) 28(3) 71 |
| rivastigmine - Exelon (New drug) 23(5) 110-1 |
| tacrine 19(1) 14-7 |
| tacrine - anticholinesterase - Cognex (new formulation) 18(2) 35-8 |
|
Amanita phalloides
|
| poisoning 23(2) 29 |
|
amantadine
|
| in influenza 25(1) 5-7 |
| in Parkinson's disease 24(4) 92-5 |
|
Amaryl
|
| see glimepiride 24(3) 71-5 |
|
ambulatory blood pressure
|
| monitoring 20(1) 18-20 |
|
AME Line
|
| consumer reporting of adverse drug reactions 27(2) 38 |
|
amenorrhoea
|
| hyperprolactinaemic - cabergoline - Dostinex (New drug) 19(1) 24-7 |
|
Amevive
|
| see alefacept 27(4) 101-5 |
|
amifostine
|
| chemotherapy chemoprotection - Ethyol (New drug) 20(1) 22-3 |
|
amino acid dipeptide
|
| Glamin (New formulation) 25(4) 94-9 |
|
aminoglutethamide
|
| breast cancer 21(1) 15-9 |
|
aminoglycosides
|
| effects on kidney 23(1) 17-9 |
| therapeutic drug monitoring (letters) 20(3) 57-60 |
|
aminophylline
|
| in asthma emergencies (letter) 20(3) 57-60 |
|
amiodarone
|
| arrhythmia 28(6) 150-4 |
| and thyroid dysfunction 17(3) 70-2 |
|
amisulpride
|
| schizophrenia - Solian (New drug) 25(5) 120-3 |
| schizophrenia - Solian (New formulation) 27(3) 76-9 |
|
amitriptyline
|
| and sleep disorders in the elderly 18(1) 21-2 |
|
amlodipine
|
| clinical pharmacology of calcium channel antagonists 20(1) 5-8 |
| dihydropyridines and nocturia 20(1) 3-4 |
|
Amohexal
|
| see amoxycillin 22(5) 125-7 |
|
amorolfine
|
| antifungal - Loceryl (New drug) 19(1) 24-7 |
|
amoxycillin
|
| Amohexal (New brand) 22(5) 125-7 |
| clavulanic acid combination - Augmentin (New formulation) 22(4) 95-8 |
| clavulanic acid combination - Augmentin - advertising standards (letter) 17(3) 55-6 |
| clavulanic acid combination - Augmentin Duo forte (New strength) 21(2) 49-55 |
| clavulanic acid combination - Ausclav (New brand) 23(3) 64-7 |
| in lower respiratory tract infections 19(2) 48-51 |
| Maxamox (New formulation) 27(1) 21-3 |
| trihydrate - DBL Amoxycillin (New brand) 23(3) 64-7 |
|
amphetamines
|
| adverse effects 29(4) 109-11 |
| in attention deficit hyperactivity disorder 18(3) 60-3 |
| letters 19(3) 59-62; 19(2) 36-8; 19(1) 3-6 |
| distribution in human milk 20(2) 35-40 |
|
amprenavir
|
| HIV - Agenerase (New drug) 25(2) 44-7 |
|
amyotrophic lateral sclerosis
|
| riluzole - Rilutek (New drug) 25(4) 94-9 |
|
anabolic steroids
|
| and sport 23(4) 76-8 |
| letter 23(5) 93-6 |
|
anaemia
|
| blood transfusion guidelines 28(2) 45-7 |
| darbepoetin - chronic renal failure - Aranesp (New drug) 25(1) 20-3 |
| epoetin beta - Neorecormon - recombinant erythropoietin (New drug) 29(4) 112-5 |
| folate and vitamin B 22(1) 16-8 |
| iron deficiency - laboratory results 20(3) 74-6 |
| iron sucrose |
Home